Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JSKN016 + tislelizumab
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JSKN016 + tislelizumab is a **combination therapy** under clinical investigation for advanced cancers, particularly **non-small cell lung cancer (NSCLC)** and **HER2-negative breast cancer**. JSKN016 is an experimental drug developed by Jiangsu Alphamab Biopharmaceuticals. Tislelizumab is a humanized IgG4 monoclonal antibody targeting **programmed cell death protein 1 (PD-1)**, functioning as an immune checkpoint inhibitor. Tislelizumab blocks the PD-1 receptor on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) on tumor and immune cells, promoting T-cell mediated antitumor activity. The combination aims to harness immune checkpoint blockade alongside novel mechanisms contributed by JSKN016, enhancing antitumor immune response. The combination is currently being evaluated in phase 1 trials for locally advanced/metastatic HER2-negative breast cancer and phase 1/2 trials for advanced NSCLC[1][3].
- Other names
- JSKN016JSKN-016JSKN 016BGB-A317BGB-A-317BGB-A 317
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on JSKN016 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JSKN016 + tislelizumab.